The U.S. Patent and Trademark Office recently issued a method
of treatment patent (U.S. Patent No. 8,507,442) to
OncoMed Pharmaceuticals, Inc.
) oncology candidate, vantictumab (OMP-18R5). The patent is set
to expire in 2029.
ACTELION LTD (ALIOF): Get Free Report
BAYER A G -ADR (BAYRY): Free Stock Analysis
GLAXOSMITHKLINE (GSK): Free Stock Analysis
ONCOMED PHARMA (OMED): Free Stock Analysis
To read this article on Zacks.com click here.
Earlier OncoMed received a U.S. composition of matter patent for
the candidate. OncoMed also has several patents and pending
patent applications for vantictumab in fourteen different
countries and in Europe.
Vantictumab, a monoclonal antibody targeting the Wnt pathway, is
currently in a phase I study for the treatment of patients
suffering from advanced solid tumors. In Jun 2013, OncoMed had
presented data from the phase I study at the American Society for
Clinical Oncology (ASCO).
Results from the study revealed that vantictumab was generally
well tolerated and ensured bone health. Moreover, favourable
pharmacodynamic effects of the candidate were observed during the
Based on these encouraging data, OncoMed now plans to initiate
three phase Ib studies on vantictumab in some specific tumor
indications later in the year. These studies will be in
combination with standard-of-care chemotherapy.
We note that OncoMed has a global strategic agreement with
) to discover, develop and commercialize novel anti-cancer stem
cell therapeutics that targets the Wnt signaling pathway.
Vantictumab is the lead program under this Wnt pathway.
We remind investors that most of the candidates at OncoMed are in
early stages of development. However, the company's collaboration
with big companies like Bayer and
) are encouraging. We expect investor focus to remain on the
company's pipeline going forward.
OncoMed currently carries a Zacks Rank #3 (Hold). Other stocks,
), are comparatively better positioned with a Zacks Rank #1